Gene Expression Alterations Induced by mRNA Vaccines

Nicolas Hulscher, M.P.H. Peter A. McCullough, M.D., M.P.H. John A. Catanzaro, N.D., Ph.D.

ABSTRACT

Messenger RNA (mRNA) vaccines harness host cellular machinery to produce antigenic proteins, but their mechanism of action (MOA) extends far beyond simple antigen presentation and innate immune triggering. They directly or indirectly induce gene-altering effects that, without rigorous safeguards, pose profound risks. Compelling multi-omic human data now provide evidence of coordinated transcriptional and proteomic reprogramming after mRNA vaccination, refuting reductive models that attribute effects solely to nonspecific lipid nanoparticle (LNP)-mediated inflammation or transient Spike protein-induced cytokine responses. Without extensive regulatory overhaul, these technologies remain inherently hazardous to human health.

Introduction

Messenger RNA (mRNA) vaccines co-opt host ribosomes for antigen synthesis, engaging cellular translation and regulatory pathways in ways that can lead to unintended gene expression aberrations and genomic instability. While initial descriptions focused on lipid nanoparticle (LNP)-driven innate immunity and adaptive responses to the Spike antigen, advanced multi-omic analyses now expose a deeper gene-altering mechanism of action (MOA) with hazardous consequences.[1-3]

Multi-omics is a term used to describe the various layers of human biology and how they interact. These layers include genomics, epigenomics, transcriptomics, proteomics, metabolomics, and phenomics. This approach reveals orchestrated shifts in host gene expression, metabolic networks, and protein homeostasis that persist long after acute inflammation subsides, raising alarms about uncontrolled molecular interactions. By integrating transcriptomics, proteomics, and genomic data, we can delineate how mRNA platforms fundamentally reshape host molecular biology, suggesting a shift from inflammation-centric views to one that integrates and prioritizes molecular surveillance and mitigation strategies. Absent robust safety gates—such as real-time genomic monitoring—and biological circuit breakers to terminate aberrant expression cascades, gene transfer technologies like mRNA vaccines are fundamentally unsafe for widespread human use (Figure 1).



Figure 1. Direct evidence of mRNA vaccine–induced gene expression reprogramming across transcriptomic, proteomic, and genomic levels.

Transcriptomic Evidence Establishing Coordinated Gene Expression Reprogramming

A pivotal transcriptomic study published in the *World Journal of Experimental Medicine* performed bulk RNA sequencing on peripheral blood from individuals experiencing new-onset adverse events and cancer diagnoses post-mRNA vaccination, benchmarked against controls. Employing differential expression and pathway enrichment analyses, this work uncovers definitive patterns of transcriptomic upheaval.[1]

Transcriptomic analyses revealed enriched gene sets unequivocally linked to mitochondrial dysfunction, proteasomal stress, ribosomal impairment, and dysregulation of translational control, demonstrating profound disruption of core cellular machinery that extends far beyond nonspecific inflammatory signaling. Both examined cohorts exhibited comprehensive transcriptomic signatures indicative of systemic shifts in gene regulation, including coordinated activation of cellular stress responses and metabolic reprogramming pathways. Although interferon-mediated and Toll-like receptor signaling pathways were detectable, they represented only a minor fraction of the overall gene network perturbations, suggesting that innate immune activation is subordinate to broader, coordinated gene-altering effects induced by mRNA vaccination.

These data demonstrate that mRNA vaccines induce a gene-altering MOA, reprogramming host expression programs across diverse cellular pathways and transcending the narrow confines of LNP-Spike inflammation. Such unchecked reprogramming underscores the urgent need for molecular surveillance tools to track these aberrations in real

time, coupled with safety gates to prevent escalation into pathological states.

Harmful Longitudinal Proteomic Reprogramming in Healthy mRNA Vaccinees

Reinforcing the transcriptomic evidence, a longitudinal proteomic analysis in *Vaccine* (2026) examined plasma proteins in healthy mRNA vaccine recipients over 24 weeks. This study captures enduring proteomic alterations, directly evidencing sustained gene expression changes at the protein level.[2]

Among the 342 quantified plasma proteins, 214 demonstrated statistically significant, time-dependent modulation, with peak alterations observed between 16 and 24 weeks post-vaccination—patterns incompatible with transient inflammatory responses. The affected proteins spanned complement activation pathways and key metabolic regulators, confirming sustained engagement of immune–metabolic axes beyond short-lived innate immune signaling. Pathway enrichment analyses revealed pervasive disruptions in carbohydrate metabolism, cofactor and vitamin pathways, and endocrine signaling, underscoring systemic, gene-driven reprogramming rather than isolated acute-phase effects. In addition, shifts in autoantibody profiles targeting specific interleukins provided clear evidence of precise, mRNA-induced immunomodulatory gene expression changes.

The duration and specificity of these proteomic shifts indicate that mRNA vaccination's MOA involves gene-altering processes, eliciting regulated systemic responses that eclipse simplistic LNP-Spike inflammatory models. These persistent changes highlight the hazards of unmitigated genetic technology, demanding biological circuit breakers—such as engineered kill switches in mRNA constructs—to rapidly neutralize aberrant protein expression and avert long-term harm.

Case Report

A multi-omic case report published in the *International Journal of Innovative Research in Medical Science* details a 31-year-old woman who developed aggressive stage IV bladder cancer within 12 months of her mRNA vaccine series. Integrated profiling of circulating tumor DNA, whole-blood RNA, and exosome proteomics revealed oncogenic driver dysregulation, DNA repair deficits, and widespread molecular instability. Critically, a host–vector chimeric sequence aligning to the vaccine's spike open reading frame (ORF) was detected in non-safe-harbor genomic regions, evidencing direct molecular interplay.[3]

In this case, oncogenic driver genes—including KRAS, PIK3CA, and ATM—exhibited markedly altered expression patterns, confirming profound transcriptional reprogramming consistent with malignant transformation. Integrated proteomic and transcriptomic profiling further established widespread, multi-system gene network perturbations and molecular instability extending beyond the tumor microenvironment. Most critically, the detection of vaccine-derived genetic sequences within host DNA fragments provides concrete evidence of exogenous mRNA sequence integration, directly implicating a gene-altering mechanism of action with potential genomic consequences.

This case exemplifies how mRNA vaccines can trigger extensive molecular disruptions, reinforcing the imperative for molecular surveillance to detect such integrations early and safety gates to block hazardous genetic technology before these events manifest clinically.

Conceptual Implications

Synthesizing these studies indicates a gene-altering MOA for mRNA vaccines: (1) Transcriptomic reprogramming across metabolism, proteostasis, and stress pathways demonstrates direct induction of host gene expression changes, not incidental inflammation from LNPs or Spike. (2) Persistent proteomic modulations in diverse pathways confirm prolonged gene-driven systemic effects, independent of innate immune transients. (3) Multi-omic case evidence of dysregulation and sequence integration proves profound molecular interactions, validating gene-altering processes as central to vaccine action.

Far from mere LNP-Spike inflammation, mRNA vaccines actively reshape host gene and protein expression landscapes, with measurable and regulated outcomes that redefine their biological impact. However, this reshaping carries inherent dangers: without embedded biological circuit breakers to interrupt aberrant cascades and comprehensive molecular surveillance to monitor genomic fidelity, these technologies risk irreversible human harm, rendering them ethically and scientifically untenable for routine deployment.

Research Priorities and Future Directions

Given the accumulating evidence of sustained gene dysregulation and genomic risk, the following research priorities are required to delineate harm, define mechanistic causality, and determine whether these platforms can ever be rendered biologically safe for human use:

- Mandate controlled longitudinal multi-omic cohorts with baseline sampling to map causal gene expression trajectories, incorporating real-time molecular surveillance protocols.
- Prioritize tissue-level profiling to reveal organ-specific gene alterations masked in circulation and integrate safety gates such as sequence-specific detection and inhibition systems for aberrant integrations.
- Conduct large-scale integrative multi-omics linking expression changes to clinical outcomes, distinguishing core mechanisms from artifacts, and develop biological circuit breakers—like self-destructing mRNA motifs—to halt dysregulated expression.

Conclusion

Multi-omic evidence now unequivocally establishes that mRNA technologies operate through a gene-altering

mechanism of action, driving coordinated transcriptional and proteomic reprogramming that extends far beyond conventional inflammation-based paradigms. Human data demonstrate persistent findings that indicate ongoing biological injury rather than transient, self-limited effects. Under these conditions, continued deployment constitutes an ethical breach, a failure of public-health duty, and a direct violation of the precautionary principle, which requires protective action when credible evidence indicates serious or potentially irreversible harm, even in the absence of complete mechanistic certainty.

The burden of proving safety rests with the technology, not the exposed population. Absent mandatory molecular surveillance, enforceable safety gates, and embedded biological circuit breakers to halt aberrant gene expression, platforms such as mRNA vaccines remain inherently dangerous to humans. Immediate and comprehensive suspension of human use is therefore required.

Nicolas Hulscher, M.P.H., is an epidemiologist with the McCullough Foundation; **Peter A, McCullough, M.D., M.P.H.,** is the President of the McCullough Foundation and chief scientific officer of the Wellness Company; and **John A., Catanzaro. N.D., Ph.D.,** is CEO and Founder of Neo7Bioscience, Contact: nichulscher@gmail.com.

Acknowledgement: AI tools were used for figure-generation purposes.

REFERENCES

1. Von Ranke NL, Zhang W, Anokhin P, et al. Synthetic messenger RNA vaccines and transcriptomic dysregulation: Evidence from new-onset adverse events and cancers post-vaccination. *World J Exp Med* 2025;15(4):113869. doi:10.5493/wjem.v15.i4.113869.
2. Chazarin B, Subramanya Bhat A, et al. Longitudinal proteomic and autoantibody signatures after mRNA vaccination in healthy individuals. *Vaccine* 2026;70:127888. doi:10.1016/j.vaccine.2025.127888.
3. Catanzaro JA, Hulscher N, McCullough PA. Genomic integration and molecular dysregulation in aggressive stage IV bladder cancer following COVID-19 mRNA vaccination. *Int J Innov Res Med Sci* 2025;10(10):380–386. doi:10.23958/ijirms/vol10-i10/2130.

AAPS Principles of Medical Policy

Medical care is a professional service, not a right. Rights (as to life, liberty, and property) may be defended by force, if necessary. Professional services are subject to economic laws, such as supply and demand, and are not properly procured by force.

Physicians are professionals. Professionals are agents of their patients or clients, not of corporations, government, insurers, or other entities. Professionals act according to their own best judgment, not government "guidelines," which soon become mandates. Physicians' decisions and procedures cannot be dictated by overseers without destroying their professionalism.

Third-party payment introduces conflicts of interest. Physicians are best paid directly by the recipients of their services. The insurer's contract should be only with subscribers, not with physicians. Patients should pay their physician a mutually agreed-upon fee; the insurer should reimburse the subscriber according to the terms of the contract.

Government regulations reduce access to care. Barriers to market entry, and regulations that impose costs and burdens on the provision of care need to be greatly reduced. Examples include insurance mandates, certificate of need, translation requirements, CLIA regulation of physician office laboratories, HIPAA requirements, FDA restrictions on freedom of speech and physicians' judgment, etc.

Honest, publicly accessible pricing and accounting ("transparency") is essential to controlling costs and optimizing access. Government and other third-party payment or price-fixing obscures the true value of a service, which can only be determined by a buyer's willingness to pay. The resulting misallocation of resources creates both waste and unavailability of services.

Confidentiality is essential to good medical care. Trust is the foundation of the patient-physician relationship. Patient confidences should be preserved; information should be released only upon patient informed consent, with rare exceptions determined by law and related to credible immediate threats to the safety or health of others.

Physicians should be treated fairly in licensure, peer review, and other proceedings. Physicians should not fear loss of their livelihood or burdensome legal expenses because of baseless accusations, competitors' malice, hospitals' attempts to silence dissent, or refusal to violate their consciences. They should be accorded both procedural and substantive due process. They do not lose the basic rights enjoyed by Americans simply because of their vocation.

Medical insurance should be voluntary. While everyone has the responsibility to pay for goods and services he uses, insurance is not the only or best way to finance medical care. It greatly increases costs and expenditures. The right to decline to buy a product is the ultimate and necessary protection against low quality, overpriced offerings by monopolistic providers.

Coverage is not care. Health plans deny payment and ration care. Their promises are often broken. The only reliable protection against serious shortages and deterioration of quality is the right of patients to use their own money to buy the care of their choice.